You are here

Our Journey in the Global Fight Against COPD

Trudell Medical International: Providing patient-focused solutions and reducing health system costs: Our journey in the global fight against COPD

 

Chronic Obstructive Pulmonary Disease (COPD) is a significant healthcare problem, with an estimated 384 million cases worldwide in 2010.1 Population aging is predicted to drive further growth, with one study forecasting a 150% increase in prevalence overall, and up to 220% in the 75 and over age group, between 2010 and 2030.2

 

“COPD is a growing and devastating disease and is a key focus area for TMI” commented Andrew Varghese, Vice President and General Manager. He added that “The company has a long and enviable history of creating innovative and superior products, supported by scientific evidence, with the goal of improving patient outcomes and reducing health system costs around the world. Because COPD is a chronic and progressive disease, management strategies need to take into account very different patient experiences. Our patient-centric approach, along with our willingness to listen to our customers and incorporate their feedback into our product development, has helped us make a contribution to Respiratory Care over the past 30 years of which we can be very proud. The last 18 months in particular have seen significant gains”.

 

Highlights include;

 

The Aerobika* device

Data on this award-winning device have been published in a number of peer-reviewed publications;

 

Significant improvements in the ease-in-bringing up sputum, forced vital capacity (FVC), quality of life and 6-minute walk distance have been shown in a randomized cross-over study that evaluated daily Aerobika* device use in COPD patients. 3HE MRI images also showed ventilation improvements (Svenningsen, et al. COPD 20163)

 

Based on evidence that up to 50% of patients with COPD also have associated bronchiectasis4 a study was undertaken in non-cystic fibrosis bronchiectasis patients to determine regional airway abnormalities with CT and MRI evaluations, as well as response to Aerobika* device use over 3 weeks. Use of the Aerobika* device resulted in clinically relevant improvement in symptoms, exercise capacity and quality of life (Svenningsen, et al. Academic Radiology, 20175).

 

A real-world study with over 800 COPD patients showed that treatment with the Aerobika* device reduced the recurrence of moderate-to-severe exacerbations by 28% and severe exacerbations by 27% in the crucial 30-day post exacerbation period, when used as an add-on to usual COPD medications. (Burudpakdee ,et al. Pulmonary Therapy 20176).

 

>> Learn more about the Aerobika* Device

 

 

 

AeroChamber Plus* Flow-Vu* Anti-Static Valved Holding Chamber (AVHC)

As the makers of the leading global brand of chambers for use with Metered Dose Inhalers (MDIs), TMI is pleased to announce that a new Adult Small Mask has been added to the line of AeroChamber Plus* Flow-Vu* AVHC. The Adult Small Mask is specifically designed for adults with smaller facial dimensions. As more elderly women with comobidities are being diagnosed with COPD, using an MDI with a chamber and mask is an easy to use and cost effective drug delivery system for this patient population.

 

>> Learn more about the AeroChamber Plus* Flow-Vu* AVHC

 

 

 

AeroCount* Dose Counter (DC)

The metered dose inhaler (MDI) remains one of the most popular delivery devices for asthma and COPD medications, but one of the most difficult challenges for patients is knowing when to replace their inhaler. A recent study of over 93,000 patients found that the integration of a dose counter into rescue inhalers could decrease emergency department admissions due to exacerbations by 45%.7 Propellant may still fire from the MDI even when there is little or no drug left, leading patients to continue to use it without the clinical benefit. The presence of a dose counter can help avoid this by ensuring patients know when to replace their device.

 

The AeroCount* integrated DC was first approved by the US FDA in conjunction with Alvesco in 2008, becoming the first approved dose counter available for pharmaceutical developers. In the last year, the second generation mode of the AeroCount* DC (TMAI-200 model, Trudell Medical International) has been approved by the FDA in conjunction with two more MDI programs8. The addition of AeroCount* DC to an inhaler provides patients with reassurance that they will know when to replace their inhaler as well as reducing the risk of taking a sub therapeutic dose by using the inhaler past the label claimed number of doses.

 

>> Learn more about the AeroCount* DC

 

 

 

AEROECLIPSE* Breath-Actuated Nebulizer (BAN)

Trudell is proud to continue a history of improvements to the treatment of COPD with the only breath actuated jet nebulizer. Over the last year the AEROECLIPSE* BAN was used in several studies focused on reducing healthcare costs and achieving better patient outcomes. In one study, it was shown that patients who received care from a Respiratory Therapist using the AEROECLIPSE* II BAN lowered the 30 day readmission rates from 13.6 to 6.1%, and reduced the number of patients that required rapid response treatements from 34.4 to 12.7%.9 In a separate study, after switching to the AEROECLIPSE* II BAN in the emergency department (ED) to treat COPD cases, admissions from ED to hospital decreased 66%.10 The study lead to standard of care changes that reduced costs while improving patient satisfaction.

 

>> Learn more about the AEROECLIPSE* BAN

 

 

 

 

 

 

1. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. Journal of global health. 2015;5(2):020415.
2. Khakban A, Sin DD, FitzGerald JM, et al. The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. Am J Respir Crit Care Med. 2017;195(3):287-291.
3. Svenningsen S, Paulin GA, Sheikh K, et al. Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD. 2016;13(1):66-74.
4. Kosmas E. Bronchiectasis in patients with COPD: an irrelevant imaging finding or clinically important phenotype? Chest. 2016;150 ((4 S)):894A.
5. Svenningsen S, Guo F, McCormack DG, Parraga G. Noncystic Fibrosis Bronchiectasis: Regional Abnormalities and Response to Airway Clearance Therapy Using Pulmonary Functional Magnetic Resonance Imaging. Academic radiology. 2017;24(1):4-12.
6. Burudpakdee C, Seetasith A, Dunne P, et al. A real-world study of 30-day exacerbation outcomes in chronic obstructive pulmonary disease (COPD) patient managed with Aerobika OPEP. Pulmonary Therapeutics. 2017.
7. Price DB, Rigazio A, Buatti Small M, Ferro TJ. Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease. Journal of asthma and allergy. 2016;9:145-154.
8. FDA. NDA 208294. 2016, and NDA 021730. 2017; https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed May 17, 2017
9. LaRoche KD, Hinkson CR, Thomazin BA, Minton-Foltz PK, Carlbom DJ. Impact of an Electronic Medical Record Screening Tool and Therapist-Driven Protocol on Length of Stay and Hospital Readmission for COPD. Respiratory care. 2016;61(9):1137-1143.
10. Saunders D. Transitioning to a Breath-Actuated Pneumatic Nebulizer in the ED and In-patient Settings; Experienced Gained from Stakeholders Involved with the Process. Paper presented at: American Association of Respiratory Care Congress2015; Tampa, FL.